Moreover, several clinical trials to evaluate the effects of NI-0101 (a humanized monoclonal antibody that interferes with TLR4 dimerization) and baclofen (a TLR3 and TLR4 signaling small molecule inhibitor) are in the progress in RA patients and MS patients [145–147]. The gene discussed is TLR4; the disease is rheumatoid arthritis.